Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Sell
13
XRAY Quote, Financials, Valuation and Earnings
Last price:
$15.33
Seasonality move
:
3.96%
Day range:
$15.53 - $16.02
52-week range:
$15.47 - $34.28
Dividend yield:
4.02%
P/E ratio:
--
P/S ratio:
0.85x
P/B ratio:
1.63x
Volume:
2.7M
Avg. volume:
2.7M
1-year change:
-53.03%
Market cap:
$3.2B
Revenue:
$3.8B
EPS (TTM):
-$4.55
Analysts' Opinion
-
Consensus RatingDentsply Sirona has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $20.40, Dentsply Sirona has an estimated upside of 28.22% from its current price of $15.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing -6.85% downside risk from its current price of $15.91.
Fair Value
-
According to the consensus of 13 analysts, Dentsply Sirona has 28.22% upside to fair value with a price target of $20.40 per share.
XRAY vs. S&P 500
-
Over the past 5 trading days, Dentsply Sirona has overperformed the S&P 500 by 5.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Dentsply Sirona does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dentsply Sirona revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Dentsply Sirona reported revenues of $905M.
Earnings Growth
-
Dentsply Sirona has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Dentsply Sirona reported earnings per share of -$2.16.
Enterprise value:
5B
EV / Invested capital:
1.23x
Price / LTM sales:
0.85x
EV / EBIT:
--
EV / Revenue:
1.33x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
17.90x
Price / Operating cash flow:
11.52x
Enterprise value / EBITDA:
84.59x
Gross Profit (TTM):
$2B
Return On Assets:
-13.47%
Net Income Margin (TTM):
-23.99%
Return On Equity:
-32.39%
Return On Invested Capital:
-18.42%
Operating Margin:
1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $3.9B | $4B | $3.8B | $1B | $905M | |
| Gross Profit | $2.1B | $2.1B | $2B | $522M | $446M | |
| Operating Income | $364M | $289M | $189M | $75M | $9M | |
| EBITDA | -$662M | $249M | -$518M | $162M | -$419M | |
| Diluted EPS | -$4.42 | -$0.62 | -$4.55 | $0.32 | -$2.16 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $1.9B | $1.9B | $2B | $1.7B | |
| Total Assets | $9.4B | $9.2B | $7.6B | $7.4B | $5.8B | |
| Current Liabilities | $1.4B | $1.3B | $1.2B | $1.4B | $1.6B | |
| Total Liabilities | $4.4B | $4.2B | $3.8B | $4.1B | $3.8B | |
| Total Equity | $4.9B | $5B | $3.8B | $3.3B | $1.9B | |
| Total Debt | $2.3B | $2.1B | $1.9B | $2.1B | $2.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $517M | $377M | $461M | $160M | $87M | |
| Cash From Investing | -$138M | -$89M | -$197M | -$20M | -$57M | |
| Cash From Financing | -$329M | -$307M | -$302M | -$128M | -$38M | |
| Free Cash Flow | $368M | $228M | $281M | $120M | $36M | |
XRAY
Sector
Market Cap
$3.2B
$36.4M
Price % of 52-Week High
46.41%
45.1%
Dividend Yield
4.02%
0%
Shareholder Yield
9.23%
-0.74%
1-Year Price Total Return
-53.03%
-39.83%
Beta (5-Year)
0.976
0.773
Dividend yield:
4.02%
Annualized payout:
$0.64
Payout ratio:
-13.85%
Growth streak:
6 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$16.24
200-day SMA
Sell
Level
$22.77
Bollinger Bands (100)
Sell
Level
17.38 - 21.94
Chaikin Money Flow
Buy
Level
241M
20-day SMA
Sell
Level
$17.70
Relative Strength Index (RSI14)
Sell
Level
30.14
ADX Line
Sell
Level
30.7
Williams %R
Buy
Level
-88.3049
50-day SMA
Sell
Level
$18.50
MACD (12, 26)
Sell
Level
-0.81
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
139.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5857)
Sell
CA Score
(Annual)
Level (-1.2982)
Buy
Beneish M-Score
(Annual)
Level (-3.9154)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.127)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dentsply Sirona is one of the world’s largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm’s wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm’s salesforce or directly to consumers (such as Byte clear aligner).
Stock Forecast FAQ
In the current month, XRAY has received 2 Buy ratings 11 Hold ratings, and 0 Sell ratings. The XRAY average analyst price target in the past 3 months is $20.40.
-
Where Will Dentsply Sirona Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dentsply Sirona share price will rise to $20.40 per share over the next 12 months.
-
What Do Analysts Say About Dentsply Sirona?
Analysts are divided on their view about Dentsply Sirona share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dentsply Sirona is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Dentsply Sirona's Price Target?
The price target for Dentsply Sirona over the next 1-year time period is forecast to be $20.40 according to 13 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is XRAY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dentsply Sirona is a Hold. 11 of 13 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of XRAY?
You can purchase shares of Dentsply Sirona via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dentsply Sirona shares.
-
What Is The Dentsply Sirona Share Price Today?
Dentsply Sirona was last trading at $15.33 per share. This represents the most recent stock quote for Dentsply Sirona. Yesterday, Dentsply Sirona closed at $15.91 per share.
-
How To Buy Dentsply Sirona Stock Online?
In order to purchase Dentsply Sirona stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
